Global Meningococcal Vaccines Market Size study, by Vaccine Serotype (MenACWY, MenB & Manic, MenC, MenA, MenAC), by Vaccine Type (Conjugate, Polysaccharide, Subcapsular), by End User (Pediatric, Adult, Travelers) and Regional Forecasts 2022-2032

Description

Global Meningococcal Vaccines Market is valued approximately at USD 3.48 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.0% over the forecast period 2024-2032. Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, encompasses severe infections like meningitis and bacteremia, which, if untreated, can result in a fatality rate as high as 50%. This disease primarily affects the brain and spinal cord linings and has the potential to cause large-scale epidemics. Transmission occurs through direct contact with respiratory or throat secretions from infected individuals or asymptomatic carriers. Out of the 12 serogroups of N. meningitidis, serogroups A, B, C, W, and Y are the major culprits responsible for the majority of global cases. The unpredictable circulation of these serogroups across different age groups and regions necessitates the availability of vaccines targeting each serogroup.

The market for meningococcal vaccines is poised for significant growth, driven by increasing adoption in national immunization programs across various countries and a rise in meningococcal outbreaks globally. These outbreaks have escalated the demand for effective vaccines, thereby propelling market growth. However, stringent regulatory frameworks for new vaccine approvals and product recalls due to contamination issues pose challenges to market expansion. On a positive note, ongoing research and development in meningococcal vaccines and rising global healthcare expenditure present lucrative growth opportunities for the market.

North America led the market in 2023, holding a revenue share of 53%, followed by Europe. The dominance of North America is attributed to favorable governmental recommendations, substantial R&D investments, a robust healthcare infrastructure, and extensive awareness campaigns. In contrast, the Asia Pacific region is anticipated to witness rapid growth during the forecast period. Factors such as a growing pediatric population and proactive government initiatives to combat the increasing prevalence of the disease contribute to this growth. Non-profit organizations in the region also play a crucial role in spreading awareness among the public and healthcare professionals, further boosting vaccine adoption.

Major market players included in this report are:

GlaxoSmithKline plc
Pfizer Inc.
Sanofi Pasteur
Merck & Co., Inc.
Novartis AG
CSL Limited
Johnson & Johnson
Bharat Biotech International Limited
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Biological E Limited
Chongqing Zhifei Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Hualan Biological Engineering Inc.
Walvax Biotechnology Co., Ltd.

The detailed segments and sub-segment of the market are explained below:

By Vaccine Serotype:

MenACWY
MenB & Manic
MenC
MenA
MenAC

By Vaccine Type:

Conjugate
Polysaccharide
Subcapsular

By End User:

Pediatric
Adult
Travelers

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Meningococcal Vaccines Market Executive Summary

1.1. Global Meningococcal Vaccines Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Vaccine Serotype
- 1.3.2. By Vaccine Type
- 1.3.3. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Meningococcal Vaccines Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Meningococcal Vaccines Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Adoption in Immunization Programs
- 3.1.2. Surge in Meningococcal Outbreaks
3.2. Market Challenges
- 3.2.1. Stringent Government Regulations
- 3.2.2. Product Recalls Due to Contamination
3.3. Market Opportunities
- 3.3.1. Increase in R&D Activities
- 3.3.2. Rising Healthcare Expenditure

Chapter 4. Global Meningococcal Vaccines Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Meningococcal Vaccines Market Size & Forecasts by Vaccine Serotype 2022-2032

5.1. Segment Dashboard
5.2. Global Meningococcal Vaccines Market: Vaccine Serotype Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. MenACWY
- 5.2.2. MenB & Manic
- 5.2.3. MenC
- 5.2.4. MenA
- 5.2.5. MenAC

Chapter 6. Global Meningococcal Vaccines Market Size & Forecasts by Vaccine Type 2022-2032

6.1. Segment Dashboard
6.2. Global Meningococcal Vaccines Market: Vaccine Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Conjugate
- 6.2.2. Polysaccharide
- 6.2.3. Subcapsular

Chapter 7. Global Meningococcal Vaccines Market Size & Forecasts by End User 2022-2032

7.1. Segment Dashboard
7.2. Global Meningococcal Vaccines Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Pediatric
- 7.2.2. Adult
- 7.2.3. Travelers

Chapter 8. Global Meningococcal Vaccines Market Size & Forecasts by Region 2022-2032

8.1. North America Meningococcal Vaccines Market
- 8.1.1. U.S. Meningococcal Vaccines Market
  - 8.1.1.1. Vaccine Serotype breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Vaccine Type breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End User breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Meningococcal Vaccines Market
8.2. Europe Meningococcal Vaccines Market
- 8.2.1. U.K. Meningococcal Vaccines Market
- 8.2.2. Germany Meningococcal Vaccines Market
- 8.2.3. France Meningococcal Vaccines Market
- 8.2.4. Spain Meningococcal Vaccines Market
- 8.2.5. Italy Meningococcal Vaccines Market
- 8.2.6. Rest of Europe Meningococcal Vaccines Market
8.3. Asia-Pacific Meningococcal Vaccines Market
- 8.3.1. China Meningococcal Vaccines Market
- 8.3.2. India Meningococcal Vaccines Market
- 8.3.3. Japan Meningococcal Vaccines Market
- 8.3.4. Australia Meningococcal Vaccines Market
- 8.3.5. South Korea Meningococcal Vaccines Market
- 8.3.6. Rest of Asia Pacific Meningococcal Vaccines Market
8.4. Latin America Meningococcal Vaccines Market
- 8.4.1. Brazil Meningococcal Vaccines Market
- 8.4.2. Mexico Meningococcal Vaccines Market
- 8.4.3. Rest of Latin America Meningococcal Vaccines Market
8.5. Middle East & Africa Meningococcal Vaccines Market
- 8.5.1. Saudi Arabia Meningococcal Vaccines Market
- 8.5.2. South Africa Meningococcal Vaccines Market
- 8.5.3. Rest of Middle East & Africa Meningococcal Vaccines Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. GlaxoSmithKline plc
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Pfizer Inc.
- 9.3.3. Sanofi Pasteur
- 9.3.4. Merck & Co., Inc.
- 9.3.5. Novartis AG
- 9.3.6. CSL Limited
- 9.3.7. Johnson & Johnson
- 9.3.8. Bharat Biotech International Limited
- 9.3.9. Serum Institute of India Pvt. Ltd.
- 9.3.10. Sinovac Biotech Ltd.
- 9.3.11. Biological E Limited
- 9.3.12. Chongqing Zhifei Biological Products Co., Ltd.
- 9.3.13. Beijing Tiantan Biological Products Co., Ltd.
- 9.3.14. Hualan Biological Engineering Inc.
- 9.3.15. Walvax Biotechnology Co., Ltd.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes